Weak or faulty quality systems can hurt a company at every stage of a product’s lifecycle. Learn how you can make data quality the flywheel that drives the business for successful outcomes. A flywheel needs lots of force to start it going. Once moving, however, it’s difficult to stop. Likewise, an enterprise-wide commitment to data quality builds momentum toward predictability, problem detection, accountability, risk mitigation, and continuous improvement.
A structural commitment to data quality—organized around the proper collection,
analysis and application of meaningful metrics and maintained by systems and
procedures that safeguard the integrity of data—is the only clear route to achieve
regulatory compliance and competitive advantage.
Other content in this Stream
How to be Smart About Pre-IND and Other Meetings With the FDA
Read our strategies on how to be smart about pre-IND meetings and tips to reap the full benefits of meeting with the FDA.
A Smart Global Regulatory Submissions Strategy is Flexible, Nuanced and Nails the Logistics
Do you have the right plan in place? Learn three critical components for successful global regulatory submissions.
Strategies for Working with Global Regulatory Agencies
Early engagement with regulatory authorities can help boost regulatory success rates and also help shorten clinical development timelines.
Understanding Regulatory Requirements in Today’s Accelerated Approval Environment
Even for drugs that may never reach market, Accelerated Pathways can help companies deploy resources more efficiently and make more timely, and cost-effective go/no-go decisions.
Phase III Trial Failures: Costly But Preventable
This article examines reasons for the high failure rate of Phase III studies and innovative approaches companies can take to mitigate risk.
Regulatory Handbook: Data Integrity: FDA And Global Regulatory Guidance
Learn the newest trends and regulatory changes as we guide you through FDA and global regulations, guidance and reports on data integrity.
FDA's Accelerated Pathways Are The New Normal
Accelerated Pathways work if you work with them -- learn how.
Early Stage Haste Creates Future Waste: Three Strategies that Integrate Your Value Story
Integrating clinical and regulatory functions from an early stage adds value to your product, reduces costs and ultimately produces a sharper, more compelling value story.
Three Ways To Thrive As Regulators Raise The Bar on Data Integrity Requirements
Take this three-pronged approach to detecting, preventing, and correcting data integrity lapses.
Leveraging IDMP Compliance to Improve Your Data and Add Value to Your Business
A sound Identification of Medicinal Products (IDMP) compliance strategy confers business advantage as it results in high quality, harmonized data that can be queried efficiently.
Beyond Compliance: Using Quality Metrics To Gain Competitive Advantage
Smart companies realize that improving data systems and quality metrics is not simply a matter of compliance; it's about transforming their business.
Faster Is The New Normal In Oncology Drug Development
Learn five risk-mitigation strategies to produce data-rich trials, better teamwork and more regulatory interaction.
Leveraging FDA's Accelerated Pathways For Market Advantage
Successfully leverage the FDA’s accelerated pathways to reach the market more quickly and enhance commercial prospects.
Closing The Communication Gap Between Developers and the FDA
To get the most out of pre-submission meetings and avoid misunderstandings follow this new framework.
The Opportunity And Pitfalls of Seeking Early Scientific Advance In The EU
While the advantages of seeking and adhering to the advice given by the EMA are clear, there are also several possible drawbacks you can avoid with these key strategies.
Bridging The Gap: Satisfying Payers In An Era of Expedited Regulatory Pathways
Ensure expedited regulatory approval effectively translates into reimbursement and patient access.
Nothing Costs More Than Failure
Learn the top reasons drugs fail to be recommended for market access.